Martin Monte E, Laber Damian A
Division of Hematology and Medical Oncology, University of Louisville, J.G. Brown Cancer Center, Kentucky 40202, USA.
Am J Hematol. 2006 Mar;81(3):186-8. doi: 10.1002/ajh.20459.
Cephalosporin-induced hemolytic anemia is an acquired form of hemolytic anemia caused by interaction of drug with the immune system. Drug adsorption, drug-dependent antibody, and autoimmune induction are the three mechanisms of hemolysis. Cefotetan-induced hemolytic anemia (CIHA) has been described to occur through all three mechanisms. We report four cases of CIHA that occurred after appropriate perioperative use of cefotetan. All of our patients developed an acute and severe hemolytic episode that caused significant symptoms and led to hospitalization within 1-2 weeks after exposure to cefotetan. The hemolytic process was self-limited, and all our patients responded to supportive measures and blood transfusion. This report adds to our knowledge of CIHA, a rare complication of cefotetan use. Our cases suggest that cefotetan-induced acute severe hemolysis is caused by membrane modification (nonimmunologic protein adsorption) in addition to immune complex formation. Prompt diagnosis and aggressive supportive measures are essential in minimizing morbidity and mortality from hemolysis. Physicians should warn their patients about this complication. Given that hemolysis occurs when the subject is no longer under direct clinical supervision, patient awareness on how to recognize signs and symptoms of hemolysis is paramount to reducing the likelihood of this potentially lethal side effect. Finally, physicians might consider restricting cefotetan use.
头孢菌素诱导的溶血性贫血是一种由药物与免疫系统相互作用引起的获得性溶血性贫血。药物吸附、药物依赖性抗体和自身免疫诱导是溶血的三种机制。头孢替坦诱导的溶血性贫血(CIHA)已被描述为通过所有这三种机制发生。我们报告了4例在围手术期适当使用头孢替坦后发生的CIHA病例。我们所有的患者都出现了急性严重溶血发作,导致了明显的症状,并在接触头孢替坦后1 - 2周内住院。溶血过程是自限性的,我们所有的患者对支持措施和输血均有反应。本报告增加了我们对CIHA(头孢替坦使用的一种罕见并发症)的认识。我们的病例表明,除免疫复合物形成外,头孢替坦诱导的急性严重溶血是由膜修饰(非免疫性蛋白质吸附)引起的。及时诊断和积极的支持措施对于将溶血的发病率和死亡率降至最低至关重要。医生应告知患者这种并发症。鉴于溶血发生在患者不再接受直接临床监护时,患者对如何识别溶血的体征和症状的认识对于降低这种潜在致命副作用的可能性至关重要。最后,医生可能会考虑限制头孢替坦的使用。